Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
National, Phase IV, Multicentric, Open Label, Comparative Study to Evaluate the Efficacy and Safety of Insulin Glargine Plus Glulisine and Sliding Scale Plus Glulisine in Hospitalized Patients With Diabetes Metabolism Type II Under Enteral Nutrition.
Primary Objective:
1- Proportion of patients with mean daily glycemia <140mg/dL during the period of 7 days of treatment with glargine plus supplemental glulisine versus patients with glulisine sliding scale.
Secondary Objective:
- Incidence of moderate hyperglycemia (>140mg/dL) during the treatment period.
- Incidence of hypoglycemia (<60mg/dL and < 40mg/dL) during the treatment period.
- Incidence of severe hyperglycemia (>400mg/dL) during the treatment period.
- Total dose of insulin and correction dose in each group.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Belo Horizonte, Brasilien, 30150-120
- Sanofi-Aventis Investigational Site Number 076-007
-
Curitiba, Brasilien, 80420-011
- Sanofi-Aventis Investigational Site Number 076-011
-
Joinville, Brasilien
- Sanofi-Aventis Investigational Site Number 076-005
-
Porto Alegre, Brasilien, 90035-001
- Sanofi-Aventis Investigational Site Number 076-001
-
Porto Alegre, Brasilien, 90035-003
- Sanofi-Aventis Investigational Site Number 076-004
-
São José do Rio Preto, Brasilien, 15090-000
- Sanofi-Aventis Investigational Site Number 076-006
-
São Paulo, Brasilien, 01232-010
- Sanofi-Aventis Investigational Site Number 076-010
-
São Paulo, Brasilien, 01308-050
- Sanofi-Aventis Investigational Site Number 076-008
-
São Paulo, Brasilien, 01323-020
- Sanofi-Aventis Investigational Site Number 076-003
-
São Paulo, Brasilien, 01323-900
- Sanofi-Aventis Investigational Site Number 076-009
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Men and women with type 2 diabetes that will need enteral nutrition with carbohydrate content.
- Glycemia >140mg/dL and < 400mg/dL at admission on the ward.
- Informed consent (patient or legally authorized representative)
Exclusion criteria:
- Hypersensibility to insulin glargine or glulisine, or any other component of the insulin formulation.
- Use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months.
- History of diabetic ketoacidosis or hyperosmolar hyperglycaemic state or ketonuria.
- Subjects with conditions that are expected to need surgery or intensive care unit (ICU)admission based on discussions with the treatment team and attending physician.
- Pregnancy.
- Severe hepatic disease or active hepatitis.
- Cardiac failure class III or IV (Classification de la New York Heart Association:NYHA).
- Diagnosed advanced autonomic neuropathy.
- Diagnosed cancer.
- Active infection.
- Current therapy with steroids.
- Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 1
Insulin Glargine + Insulin Glulisine
|
Pharmaceutical form: Lantus® (100 U/ml) Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device. Dose regimen: Single daily dose of Insulin Glargine Pharmaceutical form: Apidra® (100 U/ml) Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device Dose regimen: Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine |
|
Aktiv komparator: 2
Insulin Glulisine
|
Pharmaceutical form: Apidra® (100 U/ml) Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device Dose regimen: Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Glycaemic parameters assessment
Tidsram: During the period of 7 Days of treatment
|
During the period of 7 Days of treatment
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Incidence of moderate and severe hyperglycemia
Tidsram: During the period of 7 Days of treatment
|
During the period of 7 Days of treatment
|
|
Incidence of symptomatic, nocturnal and severe hypoglycemias
Tidsram: During the period of 7 Days of treatment
|
During the period of 7 Days of treatment
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LANTU_L_04572
- U1111-1116-9777 (Annan identifierare: UTN)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .